The CONQUEST clinical trial reaches a major milestone: 125+ sites in 24 countries 🌍
We are excited to announce that CONQUEST, the global platform clinical trial created by the SRF, now has 125 sites open and enrolling patients in 24 countries worldwide.
In this first iteration, CONQUEST is currently evaluating two investigational study drugs focused on improving therapies for people living with systemic sclerosis-associated interstitial lung disease (SSc-ILD). With its global network of scleroderma treatment centers, CONQUEST aims to make a widespread impact on scleroderma research.
“This marks a major milestone in the effort to accelerate the development of better treatments for people living with scleroderma,” says Dr. Greg Gordon, Chief Medical Officer of the SRF. Find out if you may be eligible to enroll by taking the brief pre-screener today:
#CONQUEST #srfcure #sclerodermaresearch #scleroderma
